Skip to main content

Inspira Technologies

HardwareRa'anana, IsraelFounded 2018· One of 1805 Hardware companies tracked by AMPulse

Inspira Technologies is a NASDAQ-listed medical device company that has pivoted into additive manufacturing electronics (AME) and quantum computing connectivity through the acquisition of Nano Dimension's AME and Fabrica product lines.

CEO / Founder
Dagi Ben-Noon
Team Size
11-50
Stage
Public
Total Funding
Publicly Traded
Latest Round
Post-IPO
Key Investors
YA II PN, Ltd.

Technology & Products

Key Products

INSPIRA ART100 (FDA 510(k)-cleared blood oxygenation system for cardiopulmonary bypass); INSPIRA ART500 (adaptive blood oxygenation system for awake patients); HYLA blood sensor (continuous real-time blood monitoring); AME Platform (additively manufactured electronics 3D printing system acquired from Nano Dimension); Fabrica product line (micro 3D printing); VORTX orbiting blood oxygenation technology; Cryogenic interconnects for quantum computing

Technological Advantage

Acquired Nano Dimension's AME platform (multi-material 3D printing of electronics) and Fabrica micro-AM line for $12.5M; holds FDA 510(k) clearance for ART100; growing patent portfolio including VORTX, Dual Lumen Cannula, Initiation Module, Cannula Fixation Device; team includes former Nano Dimension executives who built the AME technology.

Differentiation

Value Proposition

Originally focused on augmented respiration technology (INSPIRA ART500) to reduce reliance on mechanical ventilators, Inspira has expanded into additive manufacturing electronics (AME) — multi-material 3D printing of electronic layers — and quantum computing cryogenic interconnects, leveraging acquired IP from Nano Dimension.

How They Differentiate

Inspira differentiates through its unique dual identity: it is both a regulated medical device company with FDA-cleared products AND an AME platform provider with Nano Dimension's heritage. The AME technology enables multi-material 3D printing of electronics layers for quantum computing and defense applications — a niche that combines additive manufacturing with high-reliability electronics.

Market & Competition

Target Customers

Hospitals and ICUs (medical devices); defense and aerospace entities (AME systems for quantum computing connectivity); research universities (AME systems); quantum computing companies (cryogenic interconnects)

Industry Verticals

Medical Devices / Respiratory Care; Additive Manufacturing / 3D Printed Electronics; Quantum Computing; Defense

Competitors

Optomec Inc. (USA) — aerosol jet printing for electronics; BotFactory Inc. (USA) — 3D printed circuit boards; nScrypt Inc. (USA) — micro-dispensing for electronics

Growth & Milestones

Growth Metrics

Market cap ~$20M (April 2026); $49.5M in binding purchase orders reaffirmed for 2026; $390K purchase order from APAC university (April 2026); $2.1M cash and equivalents (June 2025)

Major Milestones

2018: Company founded; Jul 2021: IPO on NASDAQ (IINN); 2023: FDA 510(k) clearance for INSPIRA ART100 (K232788); Dec 2025: $1.8M registered direct offering + $25M SEPA with YA II PN; Apr 2026: Acquired Nano Dimension's AME platform and Fabrica product lines for up to $12.5M; Apr 2026: Delivered AME system to Tier-1 US defense entity; Apr 2026: Signed JDA with Qarakal for quantum cryogenic interconnects

Notable Customers

Tier-1 US defense entity (AME system deployment for quantum computing); Premier APAC research university ($390K purchase order); US hospitals (ART100)

https://inspira-technologies.com

Recent coverage of Inspira Technologies

Why this company matters

Inspira Technologies began as a developer of augmented respiration systems, earning FDA 510(k) clearance for the INSPIRA ART100 blood oxygenation device used in cardiopulmonary bypass. The company's product line also includes the ART500 adaptive oxygenation system for awake patients and the HYLA continuous blood sensor. In April 2026, Inspira acquired Nano Dimension's additive manufacturing electronics (AME) platform and Fabrica micro-3D printing product lines for up to $12.5 million, adding multi-material 3D printing of electronic layers to its portfolio.

The AME platform enables printing of conductive and dielectric materials in a single process, targeting applications in high-reliability electronics for defense and quantum computing. Inspira has already delivered one AME system to a tier-1 US defense entity and signed a joint development agreement with Qarakal for cryogenic interconnects used in superconducting quantum systems. A $390,000 purchase order from a premier APAC research university further validates early commercial traction in the AME segment.

On the medical side, Inspira competes with established respiratory support incumbents, while in AME it faces competitors such as Optomec (aerosol jet printing), BotFactory (3D printed circuit boards), and nScrypt (micro-dispensing). The company's dual identity as both a regulated medical device firm and an AME platform provider is unusual, but execution risk remains high given the small team size, modest market cap around $20 million, and the challenge of scaling two distinct businesses simultaneously.

Leadership includes CEO Dagi Ben-Noon, a former co-founder and COO of Nano Dimension who helped build the very AME technology Inspira now owns. The company holds granted US patents for its VORTX blood oxygenation technology and dual lumen cannula designs, plus the AME IP acquired from Nano Dimension. With $49.5 million in binding purchase orders reaffirmed for 2026 and $2.1 million in cash as of mid-2025, Inspira is an early-stage player attempting to bridge medical devices and advanced electronics manufacturing.